Literature DB >> 22036080

Lithium, phenserine, memantine and pioglitazone reverse memory deficit and restore phospho-GSK3β decreased in hippocampus in intracerebroventricular streptozotocin induced memory deficit model.

Teresa Ponce-Lopez1, Gustavo Liy-Salmeron, Enrique Hong, Alfredo Meneses.   

Abstract

Intracerebroventricular (ICV) streptozotocin (STZ) treated rat has been described as a suitable model for sporadic Alzheimer's disease (AD). Central application of STZ has demonstrated behavioral and neurochemical features that resembled those found in human AD. Chronic treatments with antioxidants, acetylcholinesterase (AChE) inhibitors, or improving glucose utilization drugs have reported a beneficial effect in ICV STZ-treated rats. In the present study the post-training administration of a glycogen synthase kinase (GSK3) inhibitor, lithium; antidementia drugs: phenserine and memantine, and insulin sensitizer, pioglitazone on memory function of ICV STZ-rats was assessed. In these same animals the phosphorylated GSK3β (p-GSK3β) and total GSK3β levels were determined, and importantly GSK3β regulates the tau phosphorylation responsible for neurofibrillary tangle formation in AD. Wistar rats received ICV STZ application (3mg/kg twice) and 2 weeks later short- (STM) and long-term memories (LTM) were assessed in an autoshaping learning task. Animals were sacrificed immediately following the last autoshaping session, their brains removed and dissected. The enzymes were measured in the hippocampus and prefrontal cortex (PFC) by western blot. ICV STZ-treated rats showed a memory deficit and significantly decreased p-GSK3β levels, while total GSK3β did not change, in both the hippocampus and PFC. Memory impairment was reversed by lithium (100mg/kg), phenserine (1mg/kg), memantine (5mg/kg) and pioglitazone (30 mg/kg). The p-GSK3β levels were restored by lithium, phenserine and pioglitazone in the hippocampus, and restored by lithium in the PFC. Memantine produced no changes in p-GSK3β levels in neither the hippocampus nor PFC. Total GSK3β levels did not change with either drug. Altogether these results show the beneficial effects of drugs with different mechanisms of actions on memory impairment induced by ICV STZ, and restored p-GSK3β levels, a kinase key of signaling cascade of insulin receptor. 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22036080     DOI: 10.1016/j.brainres.2011.09.056

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  19 in total

Review 1.  Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 2.  Streptozotocin Intracerebroventricular-Induced Neurotoxicity and Brain Insulin Resistance: a Therapeutic Intervention for Treatment of Sporadic Alzheimer's Disease (sAD)-Like Pathology.

Authors:  Pradip K Kamat; Anuradha Kalani; Shivika Rai; Santosh Kumar Tota; Ashok Kumar; Abdullah S Ahmad
Journal:  Mol Neurobiol       Date:  2015-08-23       Impact factor: 5.590

3.  Vildagliptine protects SH-SY5Y human neuron-like cells from Aβ 1-42 induced toxicity, in vitro.

Authors:  Alim Hüseyin Dokumacı; Mukerrem Betul Yerer Aycan
Journal:  Cytotechnology       Date:  2019-04-09       Impact factor: 2.058

Review 4.  Food for thought: the role of appetitive peptides in age-related cognitive decline.

Authors:  Jim R Fadel; Corinne G Jolivalt; Lawrence P Reagan
Journal:  Ageing Res Rev       Date:  2013-02-13       Impact factor: 10.895

5.  Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial.

Authors:  Khatereh Sepanjnia; Amirhossein Modabbernia; Mandana Ashrafi; Mohammad-Jafar Modabbernia; Shahin Akhondzadeh
Journal:  Neuropsychopharmacology       Date:  2012-05-02       Impact factor: 7.853

Review 6.  What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research.

Authors:  Melita Salkovic-Petrisic; Ana Knezovic; Siegfried Hoyer; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2012-08-12       Impact factor: 3.575

7.  Taurine ameliorates neurobehavioral, neurochemical and immunohistochemical changes in sporadic dementia of Alzheimer's type (SDAT) caused by intracerebroventricular streptozotocin in rats.

Authors:  Hayate Javed; Andleeb Khan; Kumar Vaibhav; Mohd Moshahid Khan; Ajmal Ahmad; Md Ejaz Ahmad; Ashafaq Ahmad; Rizwana Tabassum; Farah Islam; Mohammed M Safhi; Fakhrul Islam
Journal:  Neurol Sci       Date:  2013-05-17       Impact factor: 3.307

Review 8.  Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments.

Authors:  Margaret K King; Marta Pardo; Yuyan Cheng; Kimberlee Downey; Richard S Jope; Eléonore Beurel
Journal:  Pharmacol Ther       Date:  2013-07-31       Impact factor: 12.310

9.  Glycogen synthase kinase-3 inhibition prevents learning deficits in diabetic mice.

Authors:  Matthew R King; Nicholas J Anderson; Lucie S Guernsey; Corinne G Jolivalt
Journal:  J Neurosci Res       Date:  2013-01-30       Impact factor: 4.164

10.  Inhibitory Effect of Memantine on Streptozotocin-Induced Insulin Receptor Dysfunction, Neuroinflammation, Amyloidogenesis, and Neurotrophic Factor Decline in Astrocytes.

Authors:  N Rajasekar; Chandishwar Nath; Kashif Hanif; Rakesh Shukla
Journal:  Mol Neurobiol       Date:  2015-12-11       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.